Pinokalant

MedChemExpress

Cat. No.:	HY-124304	
CAS No.:	149759-26-2	
Molecular Formula:	$C_{41}H_{48}N_2O_9$	
Molecular Weight:	712.83	
Target:	TRP Channel; SARS-CoV	
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling; Anti-infection	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	÷ 0

BIOLOGICAL ACTIVITY	
BIOLOGICALACI	
Description	Pinokalant is a broad-spectrum and non-selectivecation channel inhibitor. Pinokalant significantly reduces cortical infarct volume. Pinokalant o improves the metabolic and electrophysiologic status of the ischemic penumbra. Pinokalant reduces lesion size on magnetic resonance images in the acute phase following middle cerebral artery occlusion in rats. Pinokalant has the potential for the research of stroke. Pinokalant also shows anti-SARS-CoV-2 activity ^[1] .
In Vivo	Pinokalant significantly reduces cortical infarct volume from 33.8 mm ³ to 24.5 mm ^{3[1]} . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Christensen T, et al. The broad-spectrum cation channel blocker pinokalant (LOE 908 MS) reduces brain infarct volume in rats: a temperature-controlled histological study. Basic Clin Pharmacol Toxicol. 2005 Apr;96(4):316-24.

[2]. Simard JM, et al. Non-selective cation channels, transient receptor potential channels and ischemic stroke. Biochim Biophys Acta. 2007 Aug;1772(8):947-57.

[3]. Serdar Durdagi, et al. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike Receptor-Binding Domain Bound with ACE2 COVID19 Target Proteins: A Virtual Drug Repurposing Study. 2020.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Product Data Sheet